Trigeminovascular Activation in Preventive Treatment of Headache Disorders

Trigeminovascular Activation in Preventive Treatment of Headache Disorders - TAPTHA

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON50257

Enrollment

138

Registered

2020-09-21

Start date

2018-12-04

Completion date

Unknown

Last updated

2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Migraine and Cluster headache

Interventions

Capsaicin

Headache disorders

Preventive treatment

Trigeminovascular system

Eligibility

Age

18 Years to 64 Years

Inclusion criteria

Inclusion criteria: Humans aged *18 years, with a history of migraine or cluster headache

Exclusion criteria

Exclusion criteria: 1. History of using neurostimulation devices within the last 2 months 2. History of botulin toxin injections in the forehead skin within the last year 3. Dermal diseases or other abnormalities on the forehead that might interfere with the measurement 4. History of sensitivity to the fruits of capsicum plants (e.g. chilli peppers) 5. Medication overuse headache 6. current use of preventive migraine/cluster headache medication. 7. Alcohol or drug abuse 6. Body mass *30kg/m2

Design outcomes

Primary

Measure	Time frame
Dermal blood flow response (Emax measured in Arbitrary Units) to capsaicin application and electrical stimulation.	—

Secondary

Measure	Time frame
plasma concentration of CGRP	—

Countries

The Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)